Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report.
HBOC
Occult cancer
Occult metastasis to para-aortic lymph node
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
18 Aug 2023
18 Aug 2023
Historique:
received:
18
04
2023
accepted:
21
07
2023
medline:
21
8
2023
pubmed:
18
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
At the time of benign gynecological surgery, a prophylactic salpingo-oophorectomy or salpingectomy is increasingly being performed concurrently to reduce the risk of future ovarian and fallopian tube cancer. We herein describe a case of hereditary breast and ovarian cancer syndrome in which a hysterectomy and bilateral adnexectomy were performed with a preoperative diagnosis of benign tumor. A detailed pathological examination revealed occult fallopian tube cancer, and additional staging surgery provided an accurate pathology diagnosis. A 72-year-old Japanese woman with a past history of breast cancer underwent a hysterectomy and bilateral oophoro-salpingectomy for the preoperative diagnosis of uterine myoma and a right para-ovarian cyst. In the detailed pathological examination, high-grade serous carcinoma of the right fallopian tube was detected incidentally, and a subsequent staging laparotomy confirmed single para-aortic lymph node metastasis. Furthermore, a mutation in germline BRCA2 was detected postoperatively, and the patient was finally diagnosed with hereditary breast and ovarian cancer syndrome. She was diagnosed with fallopian tube cancer International Federation of Gynecology and Obstetrics Stage IIIA1(i) and started on adjuvant therapy (six courses of paclitaxel and carboplatin followed by maintenance therapy with olaparib), and 18 months after surgery, she was free of disease. This is a case of fallopian tube cancer that was diagnosed incidentally and then accurately staged with additional advanced staging surgery. Even in the absence of grossly malignant findings, a detailed pathological search of the fallopian tubes and accurate staging surgery are important to make the necessary treatment decisions for the patient.
Sections du résumé
BACKGROUND
BACKGROUND
At the time of benign gynecological surgery, a prophylactic salpingo-oophorectomy or salpingectomy is increasingly being performed concurrently to reduce the risk of future ovarian and fallopian tube cancer. We herein describe a case of hereditary breast and ovarian cancer syndrome in which a hysterectomy and bilateral adnexectomy were performed with a preoperative diagnosis of benign tumor. A detailed pathological examination revealed occult fallopian tube cancer, and additional staging surgery provided an accurate pathology diagnosis.
CASE PRESENTATION
METHODS
A 72-year-old Japanese woman with a past history of breast cancer underwent a hysterectomy and bilateral oophoro-salpingectomy for the preoperative diagnosis of uterine myoma and a right para-ovarian cyst. In the detailed pathological examination, high-grade serous carcinoma of the right fallopian tube was detected incidentally, and a subsequent staging laparotomy confirmed single para-aortic lymph node metastasis. Furthermore, a mutation in germline BRCA2 was detected postoperatively, and the patient was finally diagnosed with hereditary breast and ovarian cancer syndrome. She was diagnosed with fallopian tube cancer International Federation of Gynecology and Obstetrics Stage IIIA1(i) and started on adjuvant therapy (six courses of paclitaxel and carboplatin followed by maintenance therapy with olaparib), and 18 months after surgery, she was free of disease.
CONCLUSION
CONCLUSIONS
This is a case of fallopian tube cancer that was diagnosed incidentally and then accurately staged with additional advanced staging surgery. Even in the absence of grossly malignant findings, a detailed pathological search of the fallopian tubes and accurate staging surgery are important to make the necessary treatment decisions for the patient.
Identifiants
pubmed: 37592269
doi: 10.1186/s13256-023-04095-6
pii: 10.1186/s13256-023-04095-6
pmc: PMC10436669
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
351Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Obstet Gynecol. 2015 Jan;125(1):279-281
pubmed: 25560145
Pathol Int. 2016 Jun;66(6):337-42
pubmed: 27250113
J Natl Cancer Inst. 2003 Jan 15;95(2):113-25
pubmed: 12529344
Obstet Gynecol. 2018 Apr;131(4):642-651
pubmed: 29528920
BMC Womens Health. 2014 Dec 12;14:150
pubmed: 25494812
JAMA. 1983 Dec 9;250(22):3072-6
pubmed: 6358558
Front Oncol. 2016 May 02;6:108
pubmed: 27200296
Eur J Surg Oncol. 2020 Jan;46(1):139-147
pubmed: 31521389
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Obstet Gynecol Sci. 2021 Mar;64(2):209-215
pubmed: 33321560
J Obstet Gynaecol Res. 2015 Jan;41(1):6-11
pubmed: 25330822
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
J Clin Oncol. 2014 Oct 10;32(29):3275-83
pubmed: 25199754
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
Gynecol Oncol. 2002 May;85(2):351-5
pubmed: 11972399
Int J Clin Oncol. 2019 Sep;24(9):1105-1110
pubmed: 31055694
Cancer Prev Res (Phila). 2011 Mar;4(3):463-70
pubmed: 21278312
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
J Natl Compr Canc Netw. 2021 Jan 06;19(1):77-102
pubmed: 33406487
Front Biosci (Elite Ed). 2011 Jan 01;3(2):625-34
pubmed: 21196340
Am J Clin Oncol. 2008 Feb;31(1):39-42
pubmed: 18376226
Cancer. 2000 Nov 15;89(10):2076-84
pubmed: 11066048